Chinese biopharmaceutical company Mabwell (SH:688062) announced on Tuesday the first patient dosing in the United States for a clinical study of its novel nectin-4-targeting antibody-drug conjugate (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) in triple-negative breast cancer (TNBC) patients previously treated with antibody-drug conjugate (ADC).
This is the first overseas clinical study of 9MW2821. Mabwell said that it represents a significant step in its global development of ADC therapeutics.
The multicentre clinical study aims to evaluate the efficacy and safety of BFv in TNBC patients previously treated with a taxane and an antibody-drug conjugate with a topoisomerase inhibitor payload. The first subject has been dosed at Memorial Sloan Kettering Cancer Center.
BFv is a novel Nectin-4 targeting ADC leveraging next-generation site-specific conjugation technology. BFv is protected by multiple patents in China and internationally through the PCT.
Akeso doses first patient in Phase III Ivonescimab small cell lung cancer trial
Polymer Factory-led study advances nanocarrier-based drug delivery for aggressive cancers
Freenome and Exact Sciences agree licensing deal for CRC blood test
Intas Pharmaceuticals and Accord BioPharma acquire UDENYCA (pegfilgrastim-cbqv)
SOPHiA GENETICS expands AstraZeneca partnership to advance breast cancer treatment using AI
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
Cumberland Pharmaceuticals secures Vizient contract for Vibativ 4-Vial Starter Pak